Viatris Inc. (VTRS) compared with its closest peers (OGN, REGN, ALNY, ZTS, UTHR). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Organon, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Zoetis, United Therapeutics, Amneal Pharmaceuticals, Royalty Pharma, Sarepta Therapeutics, PTC Therapeutics and Bristol-Myers Squibb share Viatris's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Organon & Co. (OGN) | $3.61B | 17.3 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $87.83B | 20.9 |
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.52B | 108.0 |
| Zoetis Inc. (ZTS) | $32.32B | 12.2 |
| United Therapeutics Corporation (UTHR) | $21.77B | 16.6 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $5.67B | 36.1 |
| Royalty Pharma plc (RPRX) | $34.14B | 41.3 |
| Sarepta Therapeutics, Inc. (SRPT) | $1.91B | -3.0 |
| PTC Therapeutics, Inc. (PTCT) | $5.93B | 9.8 |
| Bristol-Myers Squibb Company (BMY) | $137.45B | 14.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
VTRS overview · VTRS earnings · VTRS financials · VTRS KPIs · VTRS documents · VTRS ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.